lonapegsomatropin
Selected indexed studies
- Lonapegsomatropin. (, 2006) [PMID:34554672]
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. (J Clin Endocrinol Metab, 2021) [PMID:34272849]
- Lonapegsomatropin: Pediatric First Approval. (Paediatr Drugs, 2022) [PMID:34709591]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lonapegsomatropin. (2006) pubmed
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. (2021) pubmed
- Lonapegsomatropin: Pediatric First Approval. (2022) pubmed
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis. (2024) pubmed
- Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results. (2025) pubmed
- Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. (2022) pubmed
- Lonapegsomatropin (Skytrofa) for growth hormone deficiency. (2022) pubmed
- Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results. (2022) pubmed
- Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan. (2024) pubmed
- Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial. (2022) pubmed